Jill Feldman: Fantastic IASLC STARS Scholars get-together
Jill Feldman shared a post on X:
”Fantastic IASLC STARS Scholars get-together! We ate, drank, laughed, and cried, remembering friends we have lost.
We all anxiously await the amazing research to be presented at WCLC24 – a lot of science on innovative treatments and talk about cures, but not as much about helping us live better. Many of us are veteran patients – grateful to be alive but struggling with the compound cumulative effects of multiple lines of therapy. Our bodies are tired.
I implore all researchers who develop innovative treatments to also make cancer less shitty.”
Source: Jill Feldman/X
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023